 WALTHAM, Mass.--BUSINESS WIRE--Deciphera Pharmaceuticals, Inc. NASDAQ:DCPH, today announced data presentations from clinical studies of QINLOCK, the Companys switch-control tyrosine kinase inhibitor approved in the U.S. for fourth-line gastrointestinal stromal tumor GIST, to be presented at the CTOS 2020 Virtual Annual Meeting, being held November 18-21, 2020. Posters and presentations are available to meeting participants as of November 11, 2020. New data presented at the meeting includ 